title: Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
abstract: OBJECTIVE
  The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity.
  
  
  METHODS
  Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved.
  
  
  RESULTS
  The case studies showed that there is broad agreement on criteria for meeting the Truth criteria through demonstration of content, face, and construct validity; however, several issues were identified that the Filter Working Group will need to address.
  
  
  CONCLUSIONS
  These issues will require resolution to reach consensus on how Truth will be assessed for the proposed Filter 2.0 framework, for instruments to be endorsed by OMERACT.
authors.affiliation: From the Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, The Netherlands; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Division of Musculoskeletal Disease, University of Leeds, and the UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, UK; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles, Los Angeles, California, USA; Université de Lorraine, EA 4360 APEMAC, Nancy; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Oslo University Hospital and Lovisenberg Diaconal University College, Oslo, Norway; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Heerlen, The
authors.forename: Peter
authors.initials: P
authors.lastname: Tugwell
authors.forename: Maarten
authors.initials: M
authors.lastname: Boers
authors.forename: Maria-Antonietta
authors.initials: MA
authors.lastname: D'Agostino
authors.forename: Dorcas
authors.initials: D
authors.lastname: Beaton
authors.forename: Annelies
authors.initials: A
authors.lastname: Boonen
authors.forename: Clifton O
authors.initials: CO
authors.lastname: Bingham
authors.forename: Ernest
authors.initials: E
authors.lastname: Choy
authors.forename: Philip G
authors.initials: PG
authors.lastname: Conaghan
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.forename: Catia
authors.initials: C
authors.lastname: Duarte
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst
authors.forename: Francis
authors.initials: F
authors.lastname: Guillemin
authors.forename: Laure
authors.initials: L
authors.lastname: Gossec
authors.forename: Turid
authors.initials: T
authors.lastname: Heiberg
authors.forename: Désirée M
authors.initials: DM
authors.lastname: van der Heijde
authors.forename: Sarah
authors.initials: S
authors.lastname: Hewlett
authors.forename: John R
authors.initials: JR
authors.lastname: Kirwan
authors.forename: Tore K
authors.initials: TK
authors.lastname: Kvien
authors.forename: Robert B
authors.initials: RB
authors.lastname: Landewé
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
authors.forename: Mikkel
authors.initials: M
authors.lastname: Østergaard
authors.forename: Lee
authors.initials: L
authors.lastname: Simon
authors.forename: Jasvinder A
authors.initials: JA
authors.lastname: Singh
authors.forename: Vibeke
authors.initials: V
authors.lastname: Strand
authors.forename: George
authors.initials: G
authors.lastname: Wells
mesh_terms: D006801:Humans; D010043:Outcome and Process Assessment, Health Care / Q000592:standards* / Q000639:trends*; D015203:Reproducibility of Results; D012216:Rheumatic Diseases / Q000628:therapy*; D012219:Rheumatology / Q000592:standards*; D014342:Truth Disclosure
keywords: CONSTRUCT VALIDITY; CONTENT VALIDITY; FACE VALIDITY; OMERACT; OUTCOME AND PROCESS ASSESSMENT; RANDOMIZED CONTROLLED TRIALS